ArticleFrontiers in pharmacology2026
Selective inhibition of LY294002 across cloned human cardiac ion channels: implications for atrium-selective therapy in atrial fibrillation.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Atrial fibrillation (AF) is the most prevalent clinical arrhythmia, yet current antiarrhythmic pharmacotherapies have limited efficacy and pose risks of off-target ventricular block. LY294002 was reported to inhibit the ultrarapid delayed-rectifier potassium current ( Methods: The cDNAs encoding the principal pore-forming subunits of major cardiac channels-mediating Results: LY294002 inhibited all investigated currents in a concentration-dependent manner, albeit with markedly varying potencies. Based on Hill equation fits, the half-maximal inhibitory concentration (IC Conclusion: The inhibitory potency of LY294002 against
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.